🇺🇸 FDA
Pipeline program

PEGFILGRASTIM , Rinatabart Sesutecan

GCT1184-05

Phase 2 small_molecule active

Quick answer

PEGFILGRASTIM , Rinatabart Sesutecan for Locally advanced or metastatic Non-Small Cell Lung Cancer is a Phase 2 program (small_molecule) at Genmab A/S with 1 ClinicalTrials.gov record(s).

Program details

Company
Genmab A/S
Indication
Locally advanced or metastatic Non-Small Cell Lung Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials